| Vol. 7.38 – 8 October, 2021 |
| |
|
|
| Scientists reported that RGX-202, an oral small-molecule SLC6A8 transporter inhibitor, robustly inhibited creatine import in vitro and in vivo, reduced intracellular phosphocreatine and ATP levels, and induced tumor apoptosis. [Science Advances] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers reported that cGAS-STING–dependent type 1 interferon response drove intestinal regeneration and animal recovery from radiation injury. [Science Advances] |
|
|
|
| Investigators found that a novel metastasis-related protein, cell migration-inducing and hyaluronan-binding protein (CEMIP), could act as a novel adaptor protein of O-GlcNAc transferase (OGT) to promote colorectal cancer metastasis through glutamine metabolic reprogramming. [Oncogene] |
|
|
|
| To understand whether transcriptional activity of RING-finger protein 6 (RNF6) underlied its oncogenic effect, the authors performed integrated chromatin immunoprecipitation-sequencing and RNA-sequencing analysis to identify splicing factor 3b subunit 2 (SF3B2) as a potential downstream target of RNF6. [Oncogene] |
|
|
|
| Researchers identified a new long non-coding RNA (lncRNA) derived from pseudogenes WFDC21P, which has not been reported in any previous gastric cancer (GC) study. LncRNA WFDC21P was significantly upregulated in GC cells and tissues, and clinically associated with the pathological stages of advanced GC. [Cell Death & Disease] |
|
|
|
| Investigators showed that the porcine β-defensin 114 (PBD114) was an endotoxin-responsive gene expressed in intestinal epithelial cells. Analysis on expression profiling of PBD114 gene unveiled a pattern of induction in response to stimulation of various toll-like receptors. [International Journal of Biological Macromolecules] |
|
|
|
| Researchers investigated if selective blocking of neuropeptide Y (NPY) receptors, NPY1R or NPY2R, using small molecule non-peptide antagonists (BIBP-3222 for NPY1R and BIIE-0246 for NPY2R) in the colon could attenuate intestinal inflammation by lowering tumor necrosis factor levels. [Inflammatory Bowel Diseases] |
|
|
|
| A Transwell assay and xenograft nude model showed that phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP) inhibited migration and invasion of colorectal cancer cells in vitro and in vivo, respectively. [Cell Death Discovery] |
|
|
|
| Scientists developed a method to isolate viable intestinal epithelial cells, suitable to faithfully measure their metabolic function by determining extracellular glycolytic and mitochondrial flux. [Scientific Reports] |
|
|
|
| Irbesartan suppressed monocyte chemoattractant protein-1 (MCP-1) production and the accumulation of Ly6C+CCR2+ monocytes and fibrocytes in the inflamed colon, downregulated the expression of type 1 collagen and matrix metalloproteinase 9 and inhibited the development of intestinal fibrosis and tumors. [Scientific Reports] |
|
|
|
|
| The authors discuss the interplay between H. pylori and tumor-supportive cells, including mesenchymal stem cells, cancer-associated fibroblasts, tumor-associated macrophages, and myeloid derived-suppressor cells in gastric cancer. [Seminars in Cancer Biology] |
|
|
|
| Scientists provide a set of pharmacological concepts focusing on drug repurposing for treating colorectal cancer and that are relevant for the application of new drug combinations against this disease. [Drug Discovery Today] |
|
|
|
|
| Novocure and Zai Lab Limited announced that the final patient has been enrolled in a Novocure-sponsored Phase II pilot trial conducted by Zai Lab evaluating the safety and efficacy of Tumor Treating Fields in combination with chemotherapy as a first-line treatment in patients with gastric adenocarcinoma. [Novocure] |
|
|
|
| Precirix NV announced that it has dosed the first patients in its Phase I/II clinical study of CAM-H2 for the treatment of HER2-positive metastatic cancer. The trial will evaluate CAM-H2 in HER2-positive metastatic breast and gastric/gastro-esophageal cancer patients. [Precirix NV] |
|
|
|
|
| November 1 – 3, 2021 Virtual |
|
|
|
|
|
| University of Manitoba – Winnipeg, Manitoba, Canada |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| University of Oxford – Oxford, England, United Kingdom |
|
|
|
| The University of New Mexico – Albuquerque, New Mexico, United State |
|
|
|
| Novo Nordisk – Indianapolis, Indiana, United States |
|
|
|
|